Daconib
Generic Name
Dacomitinib
Manufacturer
Pfizer Inc.
Country
USA
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| daconib 45 mg tablet | ৳ 300.00 | N/A |
Description
Overview of the medicine
Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations.
Uses & Indications
Dosage
Adults
The recommended dose is 45 mg orally once daily. Continue treatment until disease progression or unacceptable toxicity.
Elderly
No specific dosage adjustment is recommended based on age.
Renal_impairment
No dosage adjustment is required for patients with mild or moderate renal impairment. Data for severe renal impairment are limited.
How to Take
Take Dacomitinib orally once daily, with or without food. Swallow the tablet whole. Do not crush, cut, or chew the tablet. If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not take two doses at the same time.
Mechanism of Action
Dacomitinib irreversibly inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR). It binds covalently to the EGFR kinase domain, preventing ATP binding and subsequent phosphorylation, thereby inhibiting cell proliferation and promoting apoptosis in EGFR-mutated cancer cells.
Pharmacokinetics
Onset
Clinical response may take several weeks to become evident.
Excretion
Mainly excreted via feces (76-81% of the dose), with a minor portion excreted in urine (1-3%).
Half life
The elimination half-life is approximately 69-83 hours, allowing for once-daily dosing.
Absorption
Oral absorption is moderate, with peak plasma concentrations (Tmax) generally reached within 6 to 12 hours. Absolute bioavailability is approximately 80%.
Metabolism
Primarily metabolized by CYP2D6 and CYP3A4, with extensive enterohepatic recirculation contributing to its long half-life. Oxidation is the major metabolic pathway.
Side Effects
Contraindications
- •Known hypersensitivity to Dacomitinib or any component of the formulation.
Drug Interactions
CYP3A4 Inducers
Strong CYP3A4 inducers may decrease Dacomitinib exposure. Avoid co-administration with strong CYP3A4 inducers.
CYP2D6 Inhibitors
Co-administration with strong CYP2D6 inhibitors may increase Dacomitinib exposure. If co-administration is necessary, consider a Dacomitinib dose reduction.
Proton Pump Inhibitors (PPIs) and H2-receptor antagonists
Co-administration with acid-reducing agents should be avoided if possible, as Dacomitinib solubility is pH-dependent. Administer Dacomitinib at least 6 hours before or 10 hours after an H2-receptor antagonist. Avoid PPIs.
Storage
Store at room temperature (20°C to 25°C), excursions permitted to 15°C to 30°C. Protect from moisture.
Overdose
There is no specific antidote for Dacomitinib overdose. In case of an overdose, discontinue Dacomitinib and initiate general supportive measures. Closely monitor the patient and treat symptoms.
Pregnancy & Lactation
Dacomitinib may cause fetal harm when administered to a pregnant woman. Advise women of reproductive potential to use effective contraception during treatment and for at least 17 days after the last dose. It is unknown whether Dacomitinib or its metabolites are present in human milk. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for at least 28 days after the last dose.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
24 to 36 months from the date of manufacture.
Availability
Hospitals and Specialty Pharmacies
Approval Status
FDA Approved
Patent Status
Patent Protected
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in